These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 16190799

  • 1. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders.
    Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, Hall S, Ermer DJ, Tsai LY, Schroeder SR, Cook EH.
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):682-92. PubMed ID: 16190799
    [Abstract] [Full Text] [Related]

  • 2. The overt aggression scale for rating aggression in outpatient youth with autistic disorder: preliminary findings.
    Hellings JA, Nickel EJ, Weckbaugh M, McCarter K, Mosier M, Schroeder SR.
    J Neuropsychiatry Clin Neurosci; 2005 Aug; 17(1):29-35. PubMed ID: 15746480
    [Abstract] [Full Text] [Related]

  • 3. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R, Miyaoka T, Inagaki T, Furuya M, Ieda M, Liaury K, Kishi K, Horiguchi J.
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [Abstract] [Full Text] [Related]

  • 4. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.
    Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, Feirsen N, Pepa L, Anagnostou E.
    Neuropsychopharmacology; 2010 Mar; 35(4):990-8. PubMed ID: 20010551
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder.
    Simeon D, Baker B, Chaplin W, Braun A, Hollander E.
    CNS Spectr; 2007 Jun; 12(6):439-43. PubMed ID: 17545954
    [Abstract] [Full Text] [Related]

  • 13. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.
    Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB.
    Neuropsychopharmacology; 2003 Jun; 28(6):1186-97. PubMed ID: 12700713
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
    Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME.
    Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
    [Abstract] [Full Text] [Related]

  • 15. Valproate-induced thrombocytopenia: a prospective monotherapy study.
    Nasreddine W, Beydoun A.
    Epilepsia; 2008 Mar; 49(3):438-45. PubMed ID: 18031547
    [Abstract] [Full Text] [Related]

  • 16. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
    Buckley PF, Paulsson B, Brecher M.
    J Affect Disord; 2007 Mar; 100 Suppl 1():S33-43. PubMed ID: 17376537
    [Abstract] [Full Text] [Related]

  • 17. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy.
    Hessen E, Lossius MI, Reinvang I, Gjerstad L.
    Epilepsia; 2006 Dec; 47(12):2038-45. PubMed ID: 17201701
    [Abstract] [Full Text] [Related]

  • 18. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
    Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, Soorya L, Hollander E.
    Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 20. Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study.
    Petty SJ, Kantor S, Lawrence KM, Berkovic SF, Collins M, Hill KD, Makovey J, Sambrook PN, O'Brien TJ, Wark JD.
    Epilepsia; 2014 Oct; 55(10):1551-7. PubMed ID: 25124647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.